$8.82M | |
$1.30 | |
$4,609.77 | |
$0.82 | |
$0.96 | |
$+0.31 | |
+31.69% | |
19M |
BioVie, Inc. (BIVI) is currently trading at $1.37 as of 2026-08-19 14:10:00, reflecting a +31.69% move ($+0.31) from the previous close.
In the short term, the stock has returned +6.05% over the past four weeks. Over the last 12 months, BioVie, Inc. has recorded a -13.96% price change, indicating a Weak performance relative to the broader market.
Over the past seven days, BioVie, Inc. has traded within a short-term range shaped by market sentiment in the PHARMACEUTICAL PREPARATIONS sector. During this period, the stock moved from its previous closing price of $1.65 to the latest recorded price of $1.37, reflecting an intraday change of +31.69%. Daily movements highlight shifts in trading volume (19,274,863), investor positioning, and reactions to macroeconomic updates.
From a momentum standpoint, BIVI has delivered a +6.05% return over the past month and a -13.96% change in the last 12 months, indicating a Weak trend relative to its broader sector peers.
You can buy and trade BIVI on MEXC in three simple steps:
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Sector | PHARMACEUTICAL PREPARATIONS |
| Company Website |
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.